The 14th Annual American Conference Institute’s (ACI) Summit on Biosimilars & Innovator Biologics will be held on June 27-28, bringing together the “who’s who” of the biosimilars and innovator biologics industries as they gather to discuss and contemplate the impact of critical developments in these industries: biologics becoming the fastest-growing class of therapeutic compounds; the incorporation of biosimilar products into the U.S. marketplace; traditional barriers toward biologics, despite the enactment of the BPCIA; and further IPR proceedings challenging patents protecting biologic medicines, including IPRs filed before any action was taken under the BPCIA.
Goodwin is a proud sponsor of the summit, and partner and Big Molecule Watch Editor-in-Chief Natasha Daughtrey will moderate a panel, “HUMIRA Biosimilar Case Study – Part I: A Matter of Exclusivity and Offset Losses.” During this session, speakers will address the launch of Amgen’s AMJEVITA and the additional HUMIRA biosimilars expected to come to market in 2023. The speakers will draw on lessons learned from the HUMIRA biosimilars and engage in a predicative analysis of what this all means for other biosimilar launches.
Partners and Big Molecule Watch editors Elaine Blais, Alexandra Lu and Josh Weinger will attend the summit.
For additional information, please click here.